February 2014
Drug Safety Labeling Changes, February 2014
Italiano
Drug Safety Labeling Changes, February 2014
Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients, and may also present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke.
The casing on some AC/DC power adapters may become loose and separate, resulting in a potential for electric shock.
Over-delivery of blood products in the populations at greatest risk may result in injuries that require medical intervention.
Symptoms of high blood sugar include excessive thirst, excessive urination, blurred vision, weakness, nausea, vomiting and abdominal pain.
Class 1 recall of computer-based system.
Risk of rare but serious adverse events associated with infusion containing particulates.
Presence of oxidized stainless steel particulate may put a patient at risk from strong magnetic field exposure such as MRI, and other adverse events resulting in serious life-threatening complications.
Lack of sterility assurance has the potential to result in surgical infection.
Il Comitato per la valutazione del rischio per la farmacovigilanza
(PRAC) dell’Agenzia Europea dei Medicinali ha completato una revisione
dei medicinali a base di domperidone e ha raccomandato modifiche d’uso
nell’Unione Europea (UE).
80.211.154.110